unknown node
unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
- unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
- unknown node
unknown node
STI & AMR · Molecular Assays · Application Insights · Lab Operations
Culture-free resistance detection: where rapid molecular AMR markers fit in stewardship
Key takeaways
Rapid molecular AMR markers earn their place by compressing isolation and de-escalation decisions from days to hours. They complement, not replace, culture-based susceptibility testing — and they deliver value only when the assay menu is matched to a specific decision point in the workflow.
- Markers change isolation and de-escalation timelines; culture remains the reference standard.
- A detected gene is not a phenotype — label and communicate marker results as such.
- Place assays at decision points: admission screening, positive blood cultures, high-risk transfers.
- Revisit the marker menu annually against your own antibiogram and regional surveillance.
Target audienceLab Director, Infectious Disease, Procurement
Review and references
Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.
2026-10-06
2026-10-06
professional use
FAQ
Common questions
Do molecular resistance markers replace culture?
No. They complement culture. Markers answer faster for the specific genes they assay, but culture and susceptibility testing remain the reference standard and quantify what markers cannot.
Which resistance markers are most commonly run on molecular platforms?
MRSA (mecA/mecC), VRE (vanA/vanB), carbapenemase families (KPC, NDM, VIM, IMP, OXA-48-like), and rifampicin-resistance mutations for tuberculosis are the established, guideline-endorsed set.
Can a negative marker screen stop empiric therapy?
Not by itself. A negative result excludes only the mechanisms assayed, and screening specimens can contain organisms below detection or mixed populations. Marker results inform, but clinical decisions still require the full picture.
How should we choose which markers to run?
Start from your institution’s antibiogram and regional surveillance data, then place assays where a faster answer changes a decision — admission screening, positive blood cultures, or outbreak investigations.